<DOC>
	<DOCNO>NCT00419445</DOCNO>
	<brief_summary>This study randomize , double-blind , placebo-controlled crossover study assess effect GTS21 ( 25 mg three time day ( tid ) , 75 mg tid , 150 mg tid ) compare placebo non-smoking adult age 18-55 diagnosis ADHD , subtype .</brief_summary>
	<brief_title>Safety Efficacy GTS21 Adults With Attention-deficit Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>3- ( 2,4-dimethoxybenzylidene ) anabaseine</mesh_term>
	<criteria>Male female age 1855 , inclusive . Diagnostic Statistical Manual Classification Mental Disorders , Fourth Edition ( DSMIV ) criterion ADHD , subtype , base detailed psychiatric evaluation include Conners ' Adult ADHD Interview DSMIV ( CAADID ) Structured Clinical Interview DSMIV ( SCID ) . A minimum Total ADHD Symptoms Index score 28 clinician administer CAARS . A Clinical Global ImpressionsSeverity ( CGIS ) score â‰¥ 4 Screening . Normal clinically insignificant ECG clinical laboratory ( e.g. , liver enzyme , complete blood count , etc . ) finding Screening . Intellectual function ageappropriate level , deem Investigator . Supine systolic diastolic blood pressure measurement &lt; 140 &lt; 90 , respectively , Screening . Written , sign date informed consent patient participate study must give patient . Females childbearing potential must negative serum beta human chorionic gonadotropin ( HCG ) pregnancy test Screening practice doublebarrier method contraception , sexually active 30 day follow administration study drug . Male patient sexually active must agree use reliable form contraception study 30 day follow administration study drug . Be fluent English ( speak , write reading ) . Any current , control ( require prohibit medication ) uncontrolled , comorbid psychiatric diagnosis ( except simple phobia ) , major depressive disorder [ dysthymia mood disorder otherwise specify ( NOS ) allow unless medication require ] , severe comorbid Axis II disorder severe Axis I disorder Post Traumatic Stress Disorder , bipolar illness , psychosis , obsessivecompulsive disorder , substance abuse disorder , symptomatic manifestation , opinion Investigator , contraindicate treatment GTS21 confound efficacy safety assessment . Any condition illness ( include clinically significant abnormal laboratory value ) , opinion Investigator , represent inappropriate risk patient and/or could confound interpretation study . Regular use nicotine product ( include 90 day Screening ) , include smoking , transdermal patch , chew tobacco , etc . ( verified via salivary cotinine level Screening ) . Current use prohibit medication medication , include herbal supplement , central nervous system ( CNS ) effect affect cognitive performance , sedate antihistamine decongestant sympathomimetics ( bronchodilator permit ) . Use another investigational product participation clinical study within 30 day prior Screening . Body Mass Index ( BMI ) &gt; 32 . Known suspected allergy , hypersensitivity , clinically significant intolerance nicotine nicotinic agonist . Clinically important abnormality urine drug screen ( exclude patient 's current ADHD stimulant , applicable ) Screening . Pregnant currently lactate . Patients previously enrol study subsequently withdraw .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder adult</keyword>
</DOC>